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New York, New York; Berlin, Germany; Mancheter, United Kingdom; Zwolle, the Netherlands;
Glasgow, United Kingdom; and Boston, MassachusettsObjectives This study sought to compare infarct size (IS) measured by magnetic resonance imaging in
patients with successful (myocardial blush grade [MBG] 2/3) versus unsuccessful (MBG 0/1)
microcirculatory reperfusion in the INFUSE-AMI (Intracoronary Abciximab and Aspiration
Thrombectomy in Patients With Large Anterior Myocardial Infarction) trial.
Background Successful microcirculatory reperfusion, deﬁned angiographically by MBG 2 or 3, is
associated with improved outcomes in patients with ST-segment elevation myocardial infarction. The
precise mechanism underlying this association is not well deﬁned.
Methods The INFUSE-AMI trial randomized 452 patients with anterior ST-segment elevation
myocardial infarction to intracoronary bolus abciximab delivered locally at the infarct lesion versus no
abciximab, and to manual thrombus aspiration versus no aspiration. The primary endpoint was IS
(percentage of left ventricular mass) at 30 days.
Results MBG 2/3 was achieved in 367 patients (81.4%). IS was signiﬁcantly lower in patients with MBG
2/3 than in those with MBG 0/1 (median: 16.7% [interquartile range (IQR): 7.0 to 22.7] vs. 19.5% [IQR:
11.1 to 29.2]; p ¼ 0.002). Intracoronary abciximab further reduced IS in patients with MBG 2/3 (median:
14.4% [IQR: 5.4 to 20.9] vs. 17.4% [IQR: 10.5 to 23.8]; p ¼ 0.01). MBG 2/3 was associated with w30%
reduction in infarct mass (p ¼ 0.002) and w90% reduction in microvascular obstruction on day 5.
Ejection fraction was higher with MBG 2/3 at 30 days: median: 50.3% (IQR: 43.8 to 57.8) versus 46.9%
(IQR: 37.5 to 54.0); p ¼ 0.004. At 30 days, the rate of death was signiﬁcantly lower (1.7% vs. 8.3%;
p ¼ 0.0008) in the MBG 2/3 group.
Conclusions MBG 2/3 occurs in 80% of ST-segment elevation myocardial infarction patients treated
with primary percutaneous coronary intervention and is associated with smaller infarct size, less
microvascular obstruction, improved ejection fraction, and signiﬁcantly lower 30-day mortality.
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Myocardial Infarction(STEMI) are directly linked to the rapidity and success of
reperfusion. Primary percutaneous coronary intervention (PCI)
is superior to ﬁbrinolytic therapy largely because it achieves
a higher rate of successful reperfusion, deﬁned as obtaining
optimal epicardial (TIMI [Thrombolysis In Myocardial
Infarction] ﬂow grade 3) and myocardial (myocardial blush
grade [MBG] 2 or 3) ﬂow at the end of the procedure (1). It is
assumed that the improved outcomes associated with primary
PCI are related to greater myocardial salvage and, hence,
a smaller infarct size (IS) (2). IS assessment is complex because
of the various stages of damage and remodeling occurring in the
ﬁrst few weeks. Initially, reperfused myocardium is edematous,
which may artiﬁcially increase the measured infarct size early
on. As remodeling occurs and edema resolves, it is easier to
determine the exact and ﬁnal IS. Yet, the correlation between
achieving optimal reperfusion, particularly at the myocardial
level, and IS has not been studied in great detail (3). In
particular, there are no data correlating MBG with later IS,
as assessed by contrast-enhanced cardiac magnetic resonance
(CMR) at 30 days, after remodeling has occurred and micro-
vascular obstruction (MVO) (4) has resolved (5,6).
We therefore set out to analyze the relationship between
angiographic markers of successful reperfusion in STEMI
patients and ISmeasured at 30 days after PCI, using the recently
performed INFUSE-AMI (Intracoronary Abciximab and
Aspiration Thrombectomy in Patients With Large Anterior
Myocardial Infarction) randomized clinical trial.
Methods
INFUSE-AMI has been described in detail (7). In brief,
452 patients with anterior STEMI and anticipated symptom
onset to reperfusion time of <5 h undergoing primary PCI
with bivalirudin anticoagulation were randomized in a 2  2
factorial design to intracoronary (IC) abciximab delivered
locally at the site of the infarct lesion via the ClearWay Rx
catheter (Atrium Medical, Hudson, New Hampshire) versus
no abciximab or to thrombus aspiration using the Export
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Manuscript received February 8, 2013; accepted March 14, 2013.IS, measured at 30 days by CMR and expressed as a
percentage of left ventricular (LV) mass in patients assigned
to IC abciximab versus no abciximab, pooled across strata of
thrombus aspiration. The secondary major endpoint was IS
in patients assigned to aspiration versus no aspiration,
pooled across strata of intracoronary abciximab. All patients
received aspirin and clopidogrel or aspirin and prasugrel. In
a subset of patients, CMR was also performed at 5 days after
myocardial infarction (MI) to measure the extent of MVO,
again expressed as a percentage of LV mass.
All images were acquired on a commercially available 1.5-T
scanner after each site was qualiﬁed by reviewing 2 recent
CMRcases performed using the imaging protocol pre-speciﬁed
for the trial. The CMR exam consisted of 2 components:
1) cine-CMR imaging for LV volumes and systolic function;
and 2) delayed-enhancement
CMR imaging for evaluation of IS,
MVO, and LV mass. Cine-CMR
imaging was performed using a 2-
dimensional breath-held, steady-
state, free-precession sequence
(parameters: 1) shortest repetition/
echo time; 2) 8-mm slice thickness
without gaps; 3) image matrix ¼
128 tow256  192 tow256; 4)
ﬁeld of view¼ 35 to 40 cm; 5) ﬂip
angle ¼ 45 tow70; 6) in-plane
spatial resolution>2.5 2.0 mm,
bandwidth 125 kHz; and 7)
temporal resolution <50 ms).
Delayed-enhancement CMR
imaging was performed using
a 2D breath-held segmented
inversion-recovery gradient-
echo sequence 10 min after
0.2mmol/kg gadolinium contrast
injection (parameters: 1) shortest
repetition/echo time; 2) 8-mm slice thickness without gaps;
3) image matrix ¼ 128 to w256  192 to w256; 4) ﬁeld
of view ¼ 35 to 40 cm; 5) ﬂip angle ¼ 15; 6) in-plane
spatial resolution greater than 2.5  2.5 mm; 7) 2-signal
averaging; and 8) bandwidth ¼ 32 to 64 kHz). All CMR
images were analyzed at an independent core laboratory
(Cardiovascular Research Foundation, New York, New
York) without knowledge of treatment assignment. Quan-
titative analysis was performed using the U.S. Food and
Drug Administration–approved ReportCard software (version
4.0 NeoSoft LLC, Waukesha, Wisconsin). LV volumes were
determined by manually tracing the endocardial borders,
excluding the papillary muscles, at end diastole and end systole
on all short-axis cine-CMR images. LVmass (the area between
the epicardial and endocardial borders) and infarct area (the
white area within the black myocardium) were segmented on
Table 1. Baseline Characteristics of the Study Patients According to Final MBG
Final MBG 0/1 Final MBG 2/3 p Value
Patient characteristics
Age, yrs 61.5 (53.0–72.5) 61.0 (51.0–70.0) 0.30
Male 73.8 (62/84) 73.8 (271/367) 1.00
BMI, kg/m2 26.2 (24.0–29.5) 26.7 (24.0–29.4) 0.96
Heart rate, beats/min 79.0 (65.0–90.0) 77.0 (66.0–88.0) 0.32
Systolic blood pressure, mm Hg 138.5 (119.0–150.0) 140.0 (120.0–155.0) 0.26
Killip classiﬁcation
I 72.6 (61/84) 83.3 (305/366) 0.02
II 14.3 (12/84) 7.7 (28/366) 0.054
III 4.8 (4/84) 0.5 (2/366) 0.01
LVEF, %, investigator estimate 39.0 (30.0–45.0) 40.0 (35.0–50.0) 0.0005
Medical history
Medically treated hypertension 33.3 (28/84) 30.8 (113/367) 0.65
Medically treated hyperlipidemia 16.7 (14/84) 15.3 (56/366) 0.76
Diabetes mellitus 13.3 (11/83) 10.9 (40/367) 0.54
Insulin-treated 6.0 (5/83) 2.5 (9/366) 0.15
Prior myocardial infarction 1.2 (1/82) 0.8 (3/367) 0.55
Prior PCI 1.2 (1/83) 2.5 (9/367) 0.70
Congestive heart failure 4.8 (4/84) 0.0 (0/365) 0.001
Smoking 51.2 (43/84) 63.0 (228/362) 0.05
Peripheral vascular disease 1.2 (1/84) 1.6 (6/366) 1.00
History of renal insufﬁciency 1.2 (1/84) 0.8 (3/367) 0.56
History of stroke or TIA 2.4 (2/84) 1.4 (5/367) 0.62
Randomization strata
Symptom onset to ﬁrst angiogram 0.03
<3 h 59.5 (50/84) 71.4 (262/367)
3 h 40.5 (34/84) 28.6 (105/367)
LAD infarct lesion 0.58
Proximal LAD 61.9 (52/84) 65.1 (239/367)
Mid LAD 45.2 (38/84) 40.9 (150/367)
Values are median (IQR) or % (n/N).
BMI ¼ body mass index; IQR ¼ interquartile range; LAD ¼ left anterior descending artery; LVEF ¼ left ventricular ejection fraction; MBG ¼
myocardial blush grade; PCI ¼ percutaneous coronary intervention; TIA ¼ transient ischemic attack.
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720the delayed-enhancement CMR images (8). To determine
regional systolic function, theLVwasdivided into16 segments,
and wall motion abnormalities were visually classiﬁed as
normal (score 0), hypokinetic (score 1), akinetic (score 2),
dyskinetic (score 3), and summed. Percentage of infarct mass
was calculated as infarct mass divided by total myocardial
mass. Correlations for interobserver variability were 0.9930
for infarct mass and 0.9699 for total myocardial mass. Corre-
lations for intraobserver variability were 0.9953 and 0.9870,
respectively.
Major adverse cardiac and cerebrovascular events including
death, reinfarction, stroke, or ischemia-driven target vessel
revascularization were recorded at 30 days, and bleeding
was assessed using the HORIZONS-AMI (Harmonizing
Outcomes With Revascularization and Stents in Acute
Myocardial Infarction), TIMI, and GUSTO (Global Use of
Strategies To Open Occluded Coronary Arteries) scales (9).Markers of reperfusion were assessed at independent,
blinded core electrocardiography (ST-segment resolution)
and angiographic (TIMI ﬂow, corrected TIMI frame
counts, and MBG) core laboratories at the Cardiovas-
cular Research Foundation, using standard deﬁnitions
(10–12). MBG was assessed according to the densitometric
method, which evaluates the maximal intensity of contrast
penetrating the infarct zone, in comparison to unaffected
territories. TIMI ﬂow grade 3 was considered successful
epicardial reperfusion, and MBG grade 2/3 was considered
successful microcirculatory (myocardial) reperfusion (13).
Statistical analysis. Continuous variables are presented as
mean  SD or median with interquartile range (IQR) and
were compared with the Wilcoxon rank-sum test. Categorical
variables are presented as proportions and were compared
with the chi-square or Fischer exact test. IS was not distrib-
uted normally and is represented only as median values.
Table 2. Procedural Characteristics of the Study Patients According to Final MBG
Final MBG 0/1 Final MBG 2/3 p Value
Target lesion % diameter stenosis 100.0 (99.0–100.0) 100.0 (95.0–100.0) 0.35
Target lesion reference vessel diameter 3.0 (3.0–3.5) 3.0 (3.0–3.5) 0.50
Target lesion length, mm 19.0 (15.0–27.0) 16.0 (12.0–24.0) 0.04
Pre-PCI thrombus 92.9 (79/85) 84.8 (313/369) 0.05
Pre-PCI collaterals 28.6 (24/84) 26.3 (97/369) 0.67
Stents per lesion, n 1.0 (1.0–2.0) 1.0 (1.0–1.0) 0.0005
>1 33.3 (29/87) 16.3 (61/374) 0.0003
Total stent length, mm 24.0 (18.0–35.0) 23.0 (16.0–30.0) 0.053
Stent type
DES only 67.4 (58/86) 80.5 (301/374) 0.008
BMS only 31.4 (27/86) 19.5 (73/374) 0.02
DES and BMS 1.2 (1/86) 0.0 (0/374) 0.19
Final % diameter stenosis 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.30
Side branch treated, any 89.4 (76/85) 79.4 (293/369) 0.03
Final distal embolization 8.2 (7/85) 1.1 (4/369) 0.001
Aspiration performed 48.8 (41/84) 52.6 (193/367) 0.53
ClearWay Rx catheter used 51.2 (43/84) 49.3 (181/367) 0.76
If randomized to ClearWay, IC abciximab infused 83.0 (44/53) 81.6 (177/217) 0.81
Thrombus aspiration followed by local infusion of abciximab 21.4 (18/84) 24.3 (89/367) 0.58
Local infusion of abciximab followed by thrombus aspiration 4.8 (4/84) 1.6 (6/367) 0.10
Local infusion of abciximab and no thrombus aspiration 26.2 (22/84) 23.7 (87/367) 0.63
Thrombus aspiration and no local infusion of abciximab 21.4 (18/84) 26.2 (96/367) 0.37
No local infusion of abciximab and no thrombus aspiration 26.2 (22/84) 24.3 (89/367) 0.71
Acute success 71.4 (60/84) 94.0 (343/365) <0.0001
Lesion success 75.9 (63/83) 95.0 (345/363) <0.0001
Procedure success 71.4 (60/84) 94.0 (343/365) <0.0001
Values are median (IQR) or % (n/N). Acute success is deﬁned as lesion and procedure success. Lesion success is deﬁned as achievement of a ﬁnal
in-stent residual diameter stenosis of <50% (by QCA) and TIMI (Thrombolysis In Myocardial Infarction) ﬂow grade 3 using any percutaneous
method. Procedure success is deﬁned as achievement of a ﬁnal in-stent diameter stenosis of <50% (by QCA) using the assigned device and with
any adjunctive devices. ClearWay Rx catheter is manufactured by Atrium Medical (Hudson, New Hampshire).
BMS ¼ bare-metal stent; DES ¼ drug-eluting stent; IC ¼ intracoronary; QCA ¼ quantitative coronary angiography; other abbreviations as in
Table 1.
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721Signiﬁcance level was set at 0.05. All analyses were performed
with SAS (version 9.2, SAS Institute, Cary, North Carolina).
Results
Of the 452 enrolled patients, MBG could be assessed at the
core laboratory in 451 patients (99.7%). MBG 2/3 was
achieved in 367 patients (81.4%). Baseline characteristics
according to ﬁnal MBG are shown in Table 1. Compared
with patients with MBG 0/1 after PCI, those with ﬁnal
MBG 2/3 were more likely to present earlier than 3 h from
symptom onset, less likely to have current or previous heart
failure, and more likely to have higher ejection fraction
before PCI.
Procedural characteristics of the study population
according to ﬁnal MBG are shown in Table 2. Patients with
unsuccessful microcirculatory reperfusion had signiﬁcantly
longer lesions, with more thrombus, and required more
stents than those in whom successful myocardial reperfusionwas achieved. The former group also had signiﬁcantly more
side branches treated and more distal embolization, resulting
in overall signiﬁcantly lower rates of procedural success
(71.4% vs. 94%; p < 0.001). There were no differences
between the groups with respect to performance of aspira-
tion thrombectomy or IC administration of abciximab or the
order in which these procedures were performed. MBG 2/3
was achieved in 184 of 228 (80.7%) and 183 of 223 (82.1%)
of the IC abciximab and no abciximab groups, respectively;
p ¼ 0.71. MBG 2/3 was achieved in 83.4% (191 of 229) vs.
79.3% (176 of 222) of patients treated with and without
thrombus aspiration, respectively; p ¼ 0.26.
Failure to restore microcirculatory reperfusion (MBG 0/1)
was also associated with a lower rate of ﬁnal TIMI ﬂow
grade 3 (75% vs. 95.1%; p < 0.0001) and higher TIMI
frame counts (Table 3). Of note, however, there was no
difference in the rates of ST-segment resolution in patients
with MBG 0/1 versus MBG 2/3 (Table 3). Among patients
with an open microcirculation, 54 had MBG 2 and 313 had
Table 3. Markers of Reperfusion and IS According to Final MBG
Final MBG 0/1 Final MBG 2/3 p Value
Final TIMI ﬂow grade 3 75.0 (63/84) 95.1 (349/367) <0.0001
Corrected TIMI frame counts 42 (32–55) 34 (28–44) 0.0005
ST-segment resolution* 67.0 (41.3–85.0) 72.9 (45.6–87.8) 0.26
>70% 47.4 (37/78) 53.3 (177/332) 0.35
30%–70% 33.3 (26/78) 29.5 (98/332) 0.51
<30% 19.2 (15/78) 17.2 (57/332) 0.67
CMR at 30 days, n ¼ 371
IS, % of LV mass 19.5 (11.1–29.2) 16.7 (7.0–22.7) 0.002
Infarct mass, g 28.2 (14.3–39.4) 19.9 (7.8–31.2) 0.002
Total abnormal wall motion score 10.0 (5.0–12.0) 7.0 (2.0–10.0) 0.002
LV ejection fraction 46.9 (37.5–54.0) 50.3 (43.8–57.8) 0.004
CMR at 5 days, n ¼ 168
Any MVO 83.3 (20/24) 51.7 (73/144) 0.003
Total MVO, g 2.6 (0.5–5.1) 0.2 (0.0–3.7) 0.02
MVO size, % of infarct mass 6.8 (3.3–11.0) 1.5 (0.0–9.4) 0.05
Total abnormal wall motion score 10.0 (8.0–12.0) 8.0 (4.0–10.0) 0.005
Values are median (IQR) or % (n/N). *Based on sum of leads with positive ST-segment elevation.
IS ¼ infarct size; LV ¼ left ventricle; CMR ¼ cardiac magnetic resonance; MVO ¼ micro-
vascular obstruction; other abbreviations as in Tables 1 and 2.
Table 4. 30-Day Clinical Outcomes in the Study Population
According to Final MBG
Final Blush 0/1 Final Blush 2/3 p Value
Death, reinfarction, TVR, or stroke 10.7 (9) 2.5 (9) 0.0004
Death, reinfarction, CHF 11.9 (10) 5.5 (20) 0.03
Death 8.3 (7) 1.7 (6) 0.0008
Target vessel reinfarction 1.3 (1) 0.6 (2) 0.48
Death or reinfarction 9.5 (8) 2.0 (7) 0.0004
Bleeding 5.0 (4) 1.4 (5) 0.04
TIMI major 3.7 (3) 0.8 (3) 0.04
TIMI minor 1.3 (1) 0.6 (2) 0.48
New onset severe heart failure 3.7 (3) 3.6 (13) 0.96
Rehospitalization for heart failure 1.3 (1) 0.3 (1) 0.24
TIA 1.3 (1) 0.0 (0) 0.03
Stroke 0.0 (0) 0.3 (1) 0.64
Any revascularization 2.5 (2) 1.4 (5) 0.46
Stent thrombosis, deﬁnite or probable 1.3 (1) 0.8 (3) 0.71
Values are Kaplan-Meier estimates expressed as % (n events).
CHF ¼ congestive heart failure; TVR ¼ target vessel revascularization; other abbreviations as
in Tables 1 and 2.
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722MBG 3 (12% and 69.4% of all patients, respectively). These
2 groups did not differ signiﬁcantly with respect to baseline
characteristics. Patients with MBG 2, compared with those
with MBG 3, however, did have lower rates of TIMI ﬂow
grade 3 (85.2% vs. 96.8%; p ¼ 0.0003), lower procedural
success (82.7% vs. 95.8%; p ¼ 0.0002), and similar rates of
ST-segment resolution.
The primary study endpoint, IS at 30 days (assessed in
352 patients, 78% of the cohort), was signiﬁcantly lower in
patients with MBG 2/3 than in those with MBG 0/1
(median: 16.7% [IQR: 7.0 to 22.7] vs. 19.5% [IQR: 11.1 to
29.2]; p ¼ 0.002) (Table 3). A similar proportion of patients
in both groups had CMR for primary endpoint eval-
uationd78% and 80%, respectively. In the 5-day IS sub-
study, there was also w30% lower infarct mass (p ¼ 0.002)
and w90% lower amount of myocardium with MVO
present. In patients with serial CMR at 5 and 30 days (n ¼
166), infarct mass declined by nearly 30% in both groups
(p ¼ 0.65). Total abnormal wall motion score was signiﬁ-
cantly lower in patients with MBG 2/3 than in those with
MBG 0/1, both at 5 days (p ¼ 0.005) and at 30 days (p ¼
0.002). Ejection fraction at 30 days was higher in MBG 2/3
than in MBG 0/1 patients at 30 days: median: 50.3% (IQR:
43.8 to 57.8) versus 46.9% (IQR: 37.5 to 54.0); p ¼ 0.004.
There were no signiﬁcant differences in LV remodeling or
function between days 5 and 30 in patients with MBG 0/1
versus 2/3. There was no signiﬁcant difference in IS between
MBG 2 and MBG 3 (median: 17.5% [IQR: 9.8 to 25.1] vs.
16.2% [IQR: 6.7 to 22.3]; p ¼ 0.32).
The differences observed in MBG were associated with
signiﬁcantly better clinical outcomes, as shown in Table 4.Speciﬁcally, at 30 days, the rate of death was signiﬁcantly
reduced in the MBG 2/3 versus 0/1 group (1.7% vs.
8.3%; p ¼ 0.0008). The MBG 2/3 group also had
signiﬁcantly less major bleeding, but similar rates of rein-
farction, stent thrombosis, heart failure, and target vessel
revascularization.
Because IC abciximab lowered IS without affecting rates of
MBG 2/3, we explored whether its effect was different in the
2 MBG groups (Table 5). There was no interaction between
abciximab effect on IS and ﬁnal MBG (p ¼ 0.12). There
were no signiﬁcant differences in MVO at 5 days and in
clinical outcome at 30 days between patients who did or did
not receive IC abciximab within each group of ﬁnal MBG.
Discussion
This is, to our knowledge, the largest study to evaluate the
relationship between angiographic markers of reperfusion,
particularly MBG, IS, and short-term outcomes after
primary PCI in STEMI. It is also the ﬁrst to evaluate this
relationship with respect to convalescent IS, assessed at 30
days. The important lessons from this analysis are as follows:
1) Angiographically successful myocardial reperfusion,
expressed as MBG 2 or 3, was associated with a lower IS
(15% as proportion of LV mass and 30% as absolute mass).
This difference is probably an underestimation of the real
difference, as all patients who died did not get cMRI at 30
days. 2) Angiographically successful reperfusion was also
associated with a 30% lower rate of MVO, detected by
CMR at 5 days after MI and a substantially lower abnormal
wall motion score. 3) As in prior studies, the reduction in IS
was linked to a substantially lower mortality at 30 days.
These observations point to the critical importance of
Table 5. IS and Clinical Outcome According to Final MBG and Abciximab Administration
MBG 0/1 þ Abciximab MBG 0/1 – Abciximab p Value MBG 2/3 þ Abciximab MBG 2/3 – Abciximab p Value
IS, % LV mass 21.1 (12.7–29.1) 19.2 (10.2–29.2) 0.73 14.4 (5.4–20.9) 17.4 (10.5–23.8) 0.01
Infarct mass, g 30.1 (14.5–40.7) 26.7 (14.3–36.8) 0.55 17.6 (6.3–28.9) 22.8 (11.1–34.1) 0.009
Total abnormal wall motion score 9.5 (5.0–12.0) 10.0 (4.0–11.0) 0.73 5.0 (1.0–10.0) 8.0 (3.0–10.0) 0.04
LV ejection fraction 46.0 (37.8–53.2) 47.0 (37.2–54.5) 0.85 51.3 (45.1–58.8) 49.3 (42.9–57.0) 0.13
Death, MI, TVR, or stroke 13.6 (6) 7.5 (3) 0.35 2.8 (5) 2.2 (4) 0.75
Death, MI, CHF 13.6 (6) 10.0 (4) 0.57 5.0 (9) 6.1 (11) 0.63
Death 11.4 (5) 5.0 (2) 0.28 1.7 (3) 1.7 (3) 0.99
Bleeding, TIMI major or minor 4.8 (2) 5.1 (2) 0.97 1.6 (3) 1.1 (2) 0.66
Values are median (IQR) or % (n).
MI ¼ myocardial infarction; other abbreviations as in Tables 1, 3, and 4.
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723achieving effective myocardial reperfusion in STEMI. These
data also may provide the mechanistic link between the
previously reported independent association between MBG
and mortality (14). Also of note, in the present study, the
robust association between MBG (a measure of microvas-
cular integrity) and IS were independent of ST-segment
resolution (a measure of myocyte integrity [15]).
Several small studies have previously examined the rela-
tionship between MBG and IS. In a series of 31 patients
undergoing primary PCI in whom CMR was performed
within the ﬁrst 7 days and at 3 months after MI (16), those
with suboptimal reperfusion (TIMI myocardial perfusion
grade <3) had larger infarct areas both early (p ¼ 0.02) and
late (p ¼ 0.03), compared with patients with normal TIMI
myocardial perfusion grade. The remodeling process was also
less favorable in the former group (p ¼ 0.03). Vincente et al.
(17) studied 39 patients with STEMI treated with primary
PCI who achieved TIMI ﬂow grade 3 and complete ST-
segment resolution. MBG 0/1 had poor sensitivity (53.8%)
and modest speciﬁcity (75%) for MVO, which was the sole
predictor of unfavorable LV remodeling (17). Using CMR as
the gold standard for IS, Riedle et al. (18) studied 95 patients
with STEMI and non-STEMI and compared quantitative
with qualitative MBG. They showed a near perfect correla-
tion between quantitative MBG and IS, which is consistent
with the data provided in our report. In a small cohort of 27
patients, Porto et al. (5) showed that increasing MBG grade
correlated with CMR IS (p ¼ 0.043) and MVO (p ¼ 0.001),
whereas ST-segment resolution >70% did not correlate with
either. In contrast, Nijveldt et al. (3) examined 60 patients
treated with primary PCI for STEMI and correlated CMR
(days 2 to 9), electrocardiogram, and angiographic ﬁndings.
They found that early (ﬁrst pass) and late (gadolinium-
enhancement) MVO (present in 57% of the patients)
correlated with incomplete ST-segment resolution, but not
with TIMI ﬂow grade or MBG. Late MVO predicted
changes in diastolic volumes at 4 months. In the largest series
before this report, Marra et al. (19) conﬁrmed our ﬁndings
that MBG 2/3 (achieved in 61% of their 294 patients)
correlated with smaller enzymatic IS and lower rate of MVO(p < 0.001 for both). In their study, CMR was performed
early, within the ﬁrst week after STEMI (19).
Our study, by virtue of its size and speciﬁc population
included (large anterior MI), extends, and broadens these
observations. Because we analyzed IS at 5 and 30 days, we
could assess both the earlier process (MVO, edema) and the
later convalescent IS after substantial edema resolution. The
relative changes in infarct mass between the 5- and 30-day
CMR did not differ between the 2 groups of MBG, which is
consistent with the concept that myocardial salvage occurs
early after reperfusion. The overall decline in infarct mass
between the 2 studies represents the process of remodeling
and resolution of edema, which initially may give the
impression of a larger MI.
These data further clarify the overall INFUSE-AMI
results. Because the patients who did and did not receive IC
abciximab had similar rates of MBG 2/3, we can conclude
that abciximab does not enhance myocardial perfusion per
se, but rather it contributes to IS reduction by favorably
affecting microthrombi present in the capillaries (and
possibly by reducing associated inﬂammation) (20,21).
Study limitations. First, our study was powered for IS and
not for MBG, and thus the observed rates between
randomized groups should be considered exploratory.
Second, more than 20% of the enrolled patients, and all
those who died within 30 days, did not have CMR, and thus
did not contribute to the actual data reported in this paper.
As such, we could not really explore the relationship between
IS and death. As described previously (7), imputations of IS
performed as sensitivity analyses did not affect the overall
trial result. Longer-term follow-up (currently ongoing to
1 year) is required to examine the late implications of MBG
and 30-day IS. Third, the lack of association between
ST-segment resolution and MBG requires additional ex-
ploration, as the electrocardiographic parameters have been
validated in numerous datasets as powerful predictors of
myocardial salvage and of clinical outcome, and our MBG
0/1 was recorded in only a small proportion of our patients
(22). Finally, these study results are conﬁned currently to
patients with left anterior descending artery infarcts.
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Despite these caveats, we conclude that angiographically
deﬁned successful myocardial reperfusiondMBG grade 2 or
3doccurred inw80% of patients treated with contemporary
primary PCI, independent of IC abciximab administration
or thrombectomy. Achieving MBG 2/3 after primary PCI
was associated with smaller IS (particularly evident when IC
abciximab was also administered to the infarct lesion site
via the ClearWay Rx catheter), smaller MVO area, lower
abnormal wall motion score, and improved ejection fraction.
All these improved markers of reperfusions translated into
signiﬁcantly lower 30-day mortality, as compared with
patients in whom microcirculatory reperfusion was not
successful. Thus, physicians should be adequately trained to
assess MBG and evaluate this measure at the end of PCI for
prognostic purposes.
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